Last reviewed · How we verify
Drug: dorzolamide/timolol
Dorzolamide inhibits carbonic anhydrase to reduce aqueous humor production, while timolol blocks beta-adrenergic receptors to further decrease intraocular pressure.
Dorzolamide inhibits carbonic anhydrase to reduce aqueous humor production, while timolol blocks beta-adrenergic receptors to further decrease intraocular pressure. Used for Elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
At a glance
| Generic name | Drug: dorzolamide/timolol |
|---|---|
| Sponsor | Aristotle University Of Thessaloniki |
| Drug class | Carbonic anhydrase inhibitor / Beta-blocker combination |
| Target | Carbonic anhydrase II / Beta-adrenergic receptors (β1 and β2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Dorzolamide is a topical carbonic anhydrase inhibitor that decreases aqueous humor secretion in the eye by inhibiting the enzyme carbonic anhydrase II. Timolol is a non-selective beta-adrenergic antagonist that reduces aqueous humor production and may increase uveoscleral outflow. Together, these complementary mechanisms provide additive intraocular pressure reduction.
Approved indications
- Elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Common side effects
- Ocular burning or stinging
- Blurred vision
- Bitter taste
- Ocular allergic reactions
- Headache
- Systemic beta-blocker effects (bradycardia, bronchospasm)
Key clinical trials
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (PHASE3)
- A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension (PHASE2)
- Circadian Rhythms of Aqueous Humor Dynamics in Humans (PHASE2)
- Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema (PHASE2, PHASE3)
- 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations (PHASE4)
- Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: dorzolamide/timolol CI brief — competitive landscape report
- Drug: dorzolamide/timolol updates RSS · CI watch RSS
- Aristotle University Of Thessaloniki portfolio CI